Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

The UK COVID-19 trend could be slow to turn despite interventions such as national lockdowns and vaccination, says GlobalData

The UK January lockdown measures should decrease the number of COVID-19 cases in the following weeks, with the possibility of falling as low as approximately 11,000 cases by January 24, 2021, says GlobalData, a leading data and analytics company. Nneoma Okeke at GlobalData comments: “This forecast is based on historical patterns of recovery that were […]
Read more

Amidst crisis in the US, Biden promises $20 billion for vaccination program, but new ideas for vaccine delivery are needed

Following the news that the incoming Biden administration promises $20 billion for a national vaccination program, Philipp Rosenbaum, PhD, Senior Infectious Diseases Analyst at GlobalData, a leading data and analytics company, offers his view: “More funding for the mass rollout of COVID-19 vaccines is urgently needed, as the US reported on average 240,000 new daily […]
Read more

Global rheumatoid arthritis market set to reach $29.1bn by 2029

The rheumatoid arthritis (RA) market is expected to grow from $26.2bn in 2019 to $29.1bn in 2029 across the eight major markets (8MM*) at a compound annual growth rate (CAGR) of 1.0%, according to GlobalData, a leading data and analytics company. The company’s latest report, ‘Rheumatoid Arthritis: Global Drug Forecast and Market Analysis to 2029’, reveals that although the […]
Read more

Immuno-oncology is expected to continue as one of the most impactful trends in the biopharmaceutical industry in 2021, says GlobalData

The immuno-oncology (IO) therapeutic area is increasingly becoming recognized as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy and other targeted treatments due to rapid and successful development of the field in recent years. The company’s latest report, ‘The State of the Biopharmaceutical Industry – 2021’, reveals that IO drug development along with personalized […]
Read more

Covishield to dominate overall COVID-19 vaccination drive in India, says GlobalData

Serum Institute of India’s (SII) Covishield and Bharat Biotech’s Covaxin have recently received emergency use authorization (EUA) in India. However, despite indigenous vaccine Covaxin’s approval, Covishield will continue to dominate the overall vaccination drive in India irrespective of other vaccine options in the near future, says GlobalData, a leading data analytics and research company. According […]
Read more

Japan aims for comprehensive COVID-19 vaccination with strong focus on pre-orders and distribution, says GlobalData

Japan is aggressively making efforts to vaccinate its population for COVID-19 with a strong focus on signing pre-orders. The country has signed multiple deals with AstraZeneca, Pfizer, Moderna and Novavax to procure sufficient COVID-19 vaccine doses with pre-orders exceeding four times of its actual population, says GlobalData, a leading data and analytics company. In October […]
Read more

Focusing on improving patient’s quality of life could advance supportive care in cancer, says GlobalData

Technological advancements in oncology, such as the introduction of immuno-oncology therapies and targeted therapies, have improved quality of life (QoL) compared to conventional treatment options, such as chemotherapy regimens. Although disparities exist between individual indications within supportive care in cancer (SCC), a concerted effort on improving QoL and an increased understanding of disease mechanisms that […]
Read more

Teva Pharmaceuticals and MedinCell’s LAI mdc-IRM faces an increasingly competitive schizophrenia market

Teva Pharmaceuticals and MedinCell are seeking to enter the long-acting injectable (LAI) schizophrenia market after their LAI mdc-IRM (risperidone ER) demonstrated a statistically significant increase in time to relapse, compared to placebo in a Phase III trial (RISE Study). However, mdc-IRM will face an increasingly competitive schizophrenia market with LAIs being developed for many of […]
Read more

Evolving type 2 diabetes digital marketing space in Japan requires existing players attention, says GlobalData

The Japanese type 2 diabetes (T2D) therapeutics market is highly competitive with several generic, branded and biosimilar products available. Among the various types of therapies, the leading class of drugs are GLP-1R agonists, DPP-4 inhibitors and SGLT-2 inhibitors. Considering the intense competition and the growth opportunities, the digital support available for T2D patients through branded […]
Read more

Pfizer-BioNTech COVID-19 vaccine has forecasted whopping $30bn in sales

Pfizer-BioNTech’s two-shot mRNA COVID-19 vaccine, BNT-162b2, is currently the leading prophylactic vaccine for COVID-19 based on forecast sales as it is expected to be the first globally available vaccine for COVID-19. BNT-162b2 is expected to generate a whopping $30bn in sales from 2020 to 2026, with peak sales of $13.9bn in 2021, says GlobalData, a […]
Read more

Pricing and reimbursement concerns remain leading impediment to industry growth in 2021, says GlobalData

In 2021, drug pricing pressure from regulators and payers will remain and aggressive negotiation tactics to drive down drug prices will continue, according to GlobalData, a leading data and analytics company. The company’s latest annual outlook report, ‘The State of the Biopharmaceutical Industry – 2021’, reveals that 49% of global industry survey respondents believe that […]
Read more

Urban China to have highest diagnosed incident cases of non-small cell lung cancer over next decade, forecasts GlobalData

Urban China is expected to have the highest number of diagnosed incident cases of non-small cell lung cancer (NSCLC) among the eight major markets 8MM* over the next decade (2019­-2029), according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Non-Small Cell Lung Cancer – Epidemiology Forecast Report to 2029, reveals that the […]
Read more

Diagnosed incident cases of hepatocellular carcinoma in urban China set to rise by 44.41% over next decade, forecasts GlobalData

The diagnosed incident cases of hepatocellular carcinoma (HCC) in urban China are expected to increase by 44.41% over the next decade (2019­-2029), according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Hepatocellular Carcinoma – Epidemiology Forecast Report to 2029, reveals that the diagnosed incident cases of HCC are expected to increase from […]
Read more

49% of clinical trial disruption due to slow enrollment

As of November 30, 2020, the top reason for disrupted clinical trials is slow enrollment, which is causing delays in 49% of trials. The other main reasons for disruptions are enrollment suspension at 35%, and delayed initiation at 16%, says GlobalData, a leading data and analytics company. Scotty Chung-Siu, Pharma Analyst at GlobalData, comments: “Although suspended […]
Read more

NovoNordisk’s Rybelsus a game changer in T2D but may face a tough road ahead as it strides into Alzheimer’s space

NovoNordisk’s decision to investigate its recently launched Type 2 Diabetes (T2D) drug Rybelsus (semaglutide) in a pivotal Phase IIIa study of patients with early Alzheimer‘s disease may allow the company to secure its position in yet another lucrative market. However, while this drug will benefit from being the first-to-market oral GLP-1RA in T2D space and capture a […]
Read more
1 … 71 72 73 74 75 … 108